CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Odyssey Therapeutics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Odyssey Therapeutics, Inc.
51 Sleeper Street
Phone: (212) 841-1000p:212 841-1000 BOSTON, MA  02210  United States Fax: (302) 655-5049f:302 655-5049
Business Summary
Odyssey Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is developing medicines that are designed to target disease pathology with an initial emphasis on the innate immune system. Its pipeline includes OD-07656, IRAK4 scaffolding inhibitor, OD-00910, TSLP/IL-33, NLRP1, and MDA5. OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2. IRAK4 scaffolding inhibitor is designed to block inflammatory signaling by the myddosome, a protein complex found in multiple cell types across tissues. OD-00910 is a monospecific, tetravalent V-body that is designed to agonize TNFR2 selectively on regulatory T cells, or Treg. TSLP/IL-33 is a bispecific protein therapeutic candidate designed to bind and block signaling from two upstream alarmins, thymic stromal lymphopoietin, or TSLP. NLRP1, an inflammasome forming pattern recognition protein that has been genetically linked to a number of inflammatory diseases.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Jeffrey M.Leiden 69 3/1/2022 3/1/2022
President, Chief Executive Officer, Founder, Director Gary D.Glick 12/1/2024
Chief Financial Officer JasonHaas 57
Executive Vice President - Enabling Sciences JeffreyHermes
Executive Vice President - Translational Medicine AnthonyOpipari

Subsidiaries
Business Name Address City State/Province Country
ODYSSEY THERAPEUTICS GMBH INDUSTRIEPARK HAuCHST GEBAaUDE G FRANKFURT

Business Names
Business Name
Daros Inc.
Demuris Limited
Immunology Discovery, LLC
6 additional Business Names available in full report.

General Information
Number of Employees: 151 (As of 12/31/2024)
Federal Tax Id: 863384382
Fax Number: (302) 655-5049


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, September 14, 2025